A Medical Device Daily

Illumina (San Diego) has reorganized its operating structure, it said in a statement, “to further leverage the synergies between its sequencing and genotyping businesses.”

Under the new structure, a newly created life sciences business unit will include all products and services related to the research market, namely the BeadArray, BeadXpress and Sequencing product lines. The company has also created a diagnostics business unit to put more focus on the emerging opportunity in molecular diagnostics. The diagnostics business unit will develop diagnostic content for the BeadXpress system, and ultimately for Illumina’s Sequencing products.

The company said that the reorganization timing is being driven by several management changes. John Stuelpnagel, senior VP/COO and general manager of Arrays has decided to move to part-time status as of April, but with a continuing role with the company working on key projects as an Illumina fellow. Additionally, he will step down from Illumina’s board.

Jay Flatley, president/CEO of Illumina, said, “Over the last few years we have experienced incredible growth. This new organizational structure provides the foundation to continue scaling our global operations and more effectively leverage our technology assets to capitalize on future opportunities. A specific result will be the acceleration of the integration of our sequencing and genotyping technologies. Additionally, it will enable us to put more focus on developing our diagnostics business.”

Christian Henry, senior VP and CFO will take on the role of acting general manager of the Sequencing business, effective immediately. In addition to his other duties, Henry manage the integration of the Sequencing business into the new combined Life Sciences Business Unit, that integration expected complete before the end of the second quarter.

Illumina makes life science tools and integrated systems for the analysis of genetic variation and biological function.